Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.15 (4.62%)
Spread: 0.10 (3.03%)
Open: 3.25
High: 3.40
Low: 3.40
Prev. Close: 3.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

Wed, 27th Mar 2024 11:02

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Norman Broadbent PLC, up 13% at 8.75 pence, 12-month range 4.50p-9.32p. The London-based recruitment firm swings to a pretax profit in 2023 of GBP309,000 from a loss of GBP338,000 in 2022. This tracks revenue rising 41% to GBP12.3 million from GBP8.7 million, partially offset by operating expenses rising 34%to GBP10.2 million from GBP7.6 million and cost of sales rising 21% to GBP1.7 million from GBP1.4 million. Chief Executive Officer Kevin Davidson comments: "We have taken the opportunity to invest further in the Company, hiring exceptional people and building our platform to take advantage of the market rebound when it comes. Our ambition remains steadfast and we will continue to pursue our aggressive growth strategy, whilst remaining profitable and cash positive, both organically and potentially through synergistic M&A opportunities...Supported by our considerable brand strength and market leading processes and technologies, we are well-positioned for continued success."

----------

Allergy Therapeutics PLC, up 11% at 3p, 12-month range 0.37p-3.20p. In the six months that ended December 31, the Sussex, England-based biotechnology company reports pretax loss widening to GBP14.9 million from GBP8.2 million a year earlier. Revenue falls 16% to GBP33.6 million from GBP39.9 million, while financial expenses soar to GBP3.2 million from GBP398,000. Chief Executive Officer Manuel Llobet comments: "2023 has been an important year, marked by a highly focused approach to our business priorities, and a steadfast commitment to our Grass and Peanut allergy research & development programmes. We have navigated the challenges of last year, resulting in more streamlined operations and improved cost-effectiveness. This progress starts to pave the way towards a return to growth." Allergy Therapeutics also notes that its lenders have agreed that a further GBP15 million may be drawn from the existing GBP40 million amended loan facility from the second quarter of calendar 2024, with the first GBP7.5 million having already been drawn down. It says this extends its cash runway into the first quarter of its financial 2025. The lenders are major shareholders SkyGem Acquisition, which is an affiliate ZQ Capital Management, alongside Southern Fox Investments.

----------

AIM - LOSERS

----------

Infrastructure India PLC, down 80% at 0.10p, 12-month range 0.10p-1.27p. In the six months that ended September 30, the infrastructure fund investing directly into assets in India reports pretax loss narrowing to GBP31.5 million from GBP62.2 million a year earlier, largely driven by foreign exchange loss narrowing to GBP3.7 million from GBP40.8 million. Shares restarted trading on Wednesday after publishing its annual results for the financial year ended March 31 on Tuesday. During this period, pretax loss widened to GBP59.2 million from GBP48.4 million a year earlier. The company says: "The group has prepared the interim results on a basis other than going concern due to the uncertainty in relation to the timing of potential transactions, ultimate receipt of sale proceeds and the specifics of any deferred consideration. This basis was considered the most appropriate method for the reporting period."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
23 Oct 2018 16:11

BlackRock Lowers Allergy Therapeutics Stake Below Threshold (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday that BlackRock Inc lowered its stake in the company to below the 5% threshold.Prior to the deal, BlackRock held a 5.1% in the

Read more
26 Sep 2018 12:42

Allergy Therapeutics Interim Loss Widens But Germany Pushes Revenue Up

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said its loss widened in the first half of 2018, but revenue rose on strong performance in Germany and a strengthening of the company

Read more
19 Jul 2018 11:08

Allergy Therapeutics To Raise GBP11 Million Via Share Issue (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it will raise up to GBP10.6 million via placing and subscription.The pharmaceutical company focused on allergy vaccines

Read more
29 May 2018 11:19

Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday.Allergy is

Read more
21 May 2018 11:49

Allergy Therapeutics Reports Positive Results From Grass Pollen Study

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday it saw positive results from its grass pollen allergy treatment phase II dose ranging study as it prepares to commence in phase III it

Read more
14 May 2018 12:24

Allergy Therapeutics Gets Positive Indications In Latest MCT Study

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC on Monday said it has received positive new data in a study investigating its microcrystalline tyrosine-based results, it said,

Read more
16 Mar 2018 17:30

DIRECTOR DEALINGS: Allergy Therapeutics Non-Executive Lifts Stake

LONDON (Alliance News) - Pharmaceutical company Allergy Therapeutics PLC said Friday Non-Executive Director Tunde Otulana acquired shares on Thursday.Otulana acquired a

Read more
7 Mar 2018 13:42

Allergy Therapeutics Profit Falls On Costs As Pivotal Year Looms

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday half year profit fell due to higher research and development costs, as the company prepares for 2018 clinical

Read more
14 Feb 2017 14:46

Allergy Therapeutics gets trial go-ahead in Spain

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received 'Clinical Trial Application' approval in Spain. The AIM-traded firm said it now expected the formulation to

Read more
14 Feb 2017 08:49

Allergy Therapeutics' House-Dust Mite Allergy Vaccine Trial Approved

Read more
2 Nov 2016 09:41

New broad patent strengthens Allergy Therapeutics portfolio

(ShareCast News) - Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process. The AIM-traded firm said the patent c

Read more
2 Nov 2016 09:29

Allergy Therapeutics Granted EU Patent For Microcrystalline Tyrosine

Read more
10 Oct 2016 11:59

Allergy Therapeutics examines potential of adjuvant portfolio

(ShareCast News) - Allergy Therapeutics will look into potential wider applications for its adjuvant technology after recent clinical research produced encouraging indications about both allergy vaccination and infectious disease applications. Microcrystalline tyrosine (MCT), an aluminium-free depot

Read more
29 Sep 2016 11:55

DIRECTOR DEALINGS: Allergy Therapeutics Chairman Lifts Stake

Read more
28 Sep 2016 10:41

DIRECTOR DEALINGS: Allergy Therapeutics Finance Boss Buys First Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.